Author:
Kockerols Camille C.B.,Geelen Inge,Levin Mark-David,Janssen Jeroen J.W.M.,Dinmohamed Avinash G.,Hoogendoorn Mels,Cornelissen Jan J.,Westerweel Peter E.
Publisher
Ferrata Storti Foundation (Haematologica)
Reference6 articles.
1. Hochhaus A, Saussele S, Rosti G.
2. Rinaldi I, Reksodiputro AH, Jusman SW. Longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronic-phase chronic myeloid leukemia: possibility of P-glycoprotein role. Asian Pac J Cancer Prev. 2019; 20(12):3689-3695.
3. Zhaleiko IO, Perekhrestenko TP, Bilko DI, Dyagil IS, Bilko NM. Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors. Exp Oncol. 2014; 36(2):112-116.
4. Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.
5. Geelen IGP, Thielen N, Janssen JJWM. Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia. Haematologica. 2017; 102(11):1842-1849.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献